- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20), Liquid meal
- Drug · Other
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Chula Vista, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 99
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20)
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Healthy
- Interventions
- Low Dose Regular insulin, High Dose Regular insulin, 0.9% Saline
- Drug · Other
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 36 Years to 55 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
- Interventions
- Canakinumab 150 mg, Placebo to Canakinumab
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more
- Conditions
- Coronary Artery Disease
- Interventions
- Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia
- Conditions
- Sepsis, Respiratory Failure, Renal Failure, Surgical Site Infection
- Interventions
- Novolin R (human recombinant Insulin)
- Drug
- Lead sponsor
- Genesys
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Grand Blanc, Michigan
- Conditions
- Alzheimer's Disease, Obesity, Diabetes Mellitus
- Interventions
- Boost (R) 5-2 diet, Healthy Living Diet
- Other
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 55 Years to 70 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Contraception
- Interventions
- Ortho-Cyclen (R), Ortho Evra (R), extended use of Ortho Evra (R)
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Diabetes Mellitus in Pregnancy, Type 2 Diabetes Mellitus (T2DM), Gestational Diabetes Mellitus, Class A2
- Interventions
- Insulin glargine, insulin NPH
- Drug
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
- Conditions
- Diabetes, Hyperglycemia
- Interventions
- Insulin Glargine, Insulin, Insulin glulisine
- Drug
- Lead sponsor
- Guillermo Umpierrez
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Regular Human Insulin, Placebo
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 289 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2020
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Post-Prandial Hyperglycemia, Post-Prandial Hypoglycemia
- Interventions
- DiAS, Afrezza low dose, Afrezza high dose
- Device · Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- U-500R
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Mild Cognitive Impairment, Metabolic Syndrome
- Interventions
- Dietary intervention
- Behavioral
- Lead sponsor
- Bristlecone Health, Inc.
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Maple Grove, Minnesota
- Conditions
- Type I Diabetes
- Interventions
- Wosulin (N or 70/30 with R), Novolin® (N or 70/30 with R)
- Biological
- Lead sponsor
- Wockhardt
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 17
- States / cities
- Tustin, California • Hialeah, Florida • Hollywood, Florida + 14 more
- Conditions
- Hyperglycemia
- Interventions
- Human regular insulin, Insulin lispro, Insulin glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 9 more
- Conditions
- Diabetes, Hyperglycemia
- Interventions
- sliding scale regular insulin, glargine basal insulin and glulisine prandial insulin
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Coral Gables, Florida
- Conditions
- Pediatric Obesity, Insulin Resistance
- Interventions
- High-fat Challenge
- Dietary Supplement
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- BIOD-531, Humalog Mix 75/25, Humulin R U-500
- Drug
- Lead sponsor
- Biodel
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Healthy Volunteers
- Interventions
- rHuPH20, Insulin Human Injection, Insulin Lispro Injection
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Intracranial Aneurysm
- Interventions
- Insulin
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Intranasal insulin, Placebo
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hyperglycemia
- Interventions
- intensive glycemic control, conventional glycemic control
- Procedure · Drug
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- End-Stage Renal Disease, Diabetes Mellitus
- Interventions
- IV Novolin R human insulin
- Drug
- Lead sponsor
- State University of New York - Downstate Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Brooklyn, New York